Buy or Sell UNH Stock Ahead of Its Upcoming Earnings?

UnitedHealth (UNH) is scheduled to report earnings on July 29, 2025, with analysts expecting $4.94 EPS on $111.6 billion revenue, signaling an anticipated profit margin contraction due to escalating medical costs despite projected revenue growth. Historically, UNH shares have experienced positive one-day returns post-earnings in 53% of cases over the past five years, with a median gain of 4.0%, though this trend softens to 45% over the last three years, providing key context for event-driven trading strategies.

Analysis

UnitedHealth (UNH) is approaching its July 29, 2025, earnings report with a clear focus on margin pressure, a sentiment reflected in the mildly negative score of -0.2 for the ticker. Analyst consensus anticipates a significant contraction in profitability, with earnings per share (EPS) projected at $4.94, a sharp decrease from $6.80 in the prior-year quarter. This expected decline in EPS is particularly notable as it contrasts with a substantial forecasted revenue increase to $111.6 billion from $98.86 billion, squarely attributing the margin erosion to escalating medical costs. While the company's trailing twelve-month fundamentals show robust operations with $410 billion in revenue and $22 billion in net income, the forward-looking estimates create a challenging narrative. Historically, the stock has reacted positively one day after earnings in 53% of instances over the last five years, with a median gain of 4.0%. However, this pattern has weakened, dropping to a 45% frequency of positive returns over the most recent three years, suggesting that historical performance may be a less reliable guide for this specific event given the significant headwinds.

Key Decisions for Investors

• Investors should scrutinize the earnings release for any deviation from the $4.94 EPS estimate and, more critically, analyze management's commentary on the medical cost ratio and forward guidance, as this will be the primary driver of the stock's performance.
• Given the weakening trend in positive post-earnings reactions and the negative sentiment surrounding profitability, traders should be cautious with pre-earnings long positions and may consider waiting for the post-release price action to confirm a directional bias.
• Long-term investors might consider any significant price weakness post-earnings as a potential opportunity, contingent on the fundamental revenue growth story remaining intact and a credible management strategy to contain cost pressures.
• Consider using options to define risk around the event, as the wide divergence between strong top-line growth and expected bottom-line contraction creates the potential for significant price volatility in either direction.